Kornimate/medical-research-clean huggingface dataset:
effect of music on nursing students' skills, anxiety

Conditions: Music

Summary: objectives: this study aimed to determine the effect of music on nursing students' skills, anxiety, self-confidence perception, and vital signs.

design: single-blinded study with parallel groups. setting: faculty of nursing. participants: sixty first-year students who took the nursing fundamentals course were randomly assigned to the intervention (n = 30) and control (n = 30) groups. methods: data were collected using the student information form, subjective self-confidence assessment tool, and state anxiety scale from april 6 to 11, 2022. the students in the intervention group listened to music for 15 min before and during the peripheral intravenous catheter placement skill practice, while no intervention was applied in the control group.

Eligibility criteria:
inclusion criteria: * taking the nursing fundamentals course for the first time * not placing an iv catheter before * volunteering to work exclusion criteria: * being a healthy vocational high school graduate * being a foreign student

Keywords: nursing student intravenous catheter anxiety music self-confidence
interactive survivorship program for the improvement of healthcare resources in adolescent and young adult cancer survivors, inspire-aya study

Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8; Clinical Stage II Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Melanoma AJCC v8; Hematopoietic and Lymphoid Cell Neoplasm; Invasive Malignant Neoplasm; Leukemia; Lymphoma; Malignant Solid Neoplasm; Sarcoma; Stage I Colorectal Cancer AJCC v8; Stage II Colorectal Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Thyroid Gland Carcinoma

Summary: this trial studies how well an interactive survivorship program works in improving healthcare resources in adolescent and young adult cancer survivors. by improving access to survivorship resources, health literacy, self-management skills, and support, an interactive survivorship program may help to improve adherence to adolescent and young adult healthcare guidelines and reduce cancer-related distress.

outline: patients who have one or more elevated distress or low cardiometabolic or cancer health care adherence are randomized to arm i or ii. arm i (intervention): patients receive a personalized survivorship care plan (scp) and use the interactive survivorship program to improve healthcare resources (inspire) mobile application. patients may receive telehealth stepped care after 1 month. arm ii (control): patients receive access to a study-specific control website that has annotated links to existing resources for adolescent and young adult (aya) survivors. after 12 months, patients receive a personalized scp and have access to the digital inspire intervention program without telehealth calls.

Eligibility criteria:
inclusion criteria: * diagnosed with a first invasive malignancy of leukemia, lymphoma, melanoma, sarcoma, breast, thyroid, or colorectal cancer (stage 1-3 for solid tumors) between the ages of 15-39 years * current age \>= 18 when approached * currently within 1 to 5 years from the time of diagnosis * completed active treatment for disease \>= 6 months previously * received a therapeutic intervention (with curative intent if advanced stage disease) that included any of the following modalities: surgery, cytotoxic chemotherapy, biological or targeted agents, radiation therapy * english proficiency adequate to complete assessments * access to email and smartphone mobile app and or internet exclusion criteria: * diagnosed with a subsequent invasive malignancy other than non-melanoma skin cancer * received hematopoietic stem cell transplant * health issues prohibiting computer use or ability to comply with study procedures * residing in an institution or other living situation where health care decisions are not made by the participant (e.g., hospitalized, prisoners, living in a rehabilitation facility) * does not complete baseline patient reported outcome (pro) assessment items required to determine stratification or whether the survivor meets inclusion and exclusion criteria
metabolic syndrome and gen-polymorphs influence on weightloss among children in treatment for overweight

Conditions: Childhood Obesity; NAFLD (Non-alcoholic Fatty Liver Disease); Hypertension; Hyperlipidemia; Insulin Sensitivity

Summary: definition: the overall objective is to examine childhood obesity with focus on nafld and its treatment. further, we aimed to investigate the impact of genetic variation on obesity. the specific aims are to; * describe the degree of nafld among overweight and obese, danish children. (hypothesis; the degree for pediatric nafld among danish children was equal that found in other caucasian paediatric study populations). * investigate the effect of a multidisciplinary intervention treatment of 1 year on liver fat content. (hypothesis; the intervention could reduce the liver fat percentage and a reduction in bmi sds would associate with a reduction in liver fat content) - analyze changes in liver fat content in relation to changes in levels of fasting blood variables to see if any of them could be used as a clinical tool for monitoring hepatic steatosis in the clinic. (hypothesis; serum aminotransferases (separately and their ratio, respectively), serum insulin, and homa-ir could predict improvement in liver fat content - investigate the association between genetic variants and obesity.


Eligibility criteria:
inclusion criteria: * 5- 20 years old. * adipose. bmi \> 90 % percentile * new patient in the children's obesity clinic, paediatric department, university hospital holbaek,region zealand, denmark * informed consent exclusion criteria: * drop-outs
acrysof® iq restor® +2.5 d multifocal intraocular lens (iol) model sn6ad2 [sv25t0] in japan

Conditions: Cataracts

Summary: the purpose of this study is to evaluate safety and effectiveness of acrysof® iq restor® +2.5 d multifocal iol model sn6ad2 \[sv25t0\] in japanese cataract patients.

each subject completed a preoperative examination of both eyes, implantation of iol at the operative visit for each eye, and up to 8 postoperative visits (each eye examined at day 1-2, day 7-14, and day 30-60, with binocular visits at day 120-180 and day 330-420 after the second implantation). the second implantation occurred within 30 days of the first.

Eligibility criteria:
inclusion criteria: * sign informed consent; * diagnosed with bilateral cataracts; * planned cataract removal by phacoemulsification; * potential postoperative visual acuity of 0.5 decimal or better in both eyes; * preoperative astigmatism ≤ 1.5 diopter; * clear intraocular media other than cataract in study eyes; * calculated lens power within the available range; * able to undergo second eye surgery within 30 days of the first eye surgery; * other protocol-defined inclusion criteria may apply. exclusion criteria: * significant irregular corneal aberration as demonstrated by corneal topography; * any inflammation or edema (swelling) of the cornea; * diagnosed degenerative visual disorders predicted to cause future acuity losses to a level worse than 0.5 decimal; * diabetic retinopathy; * previous refractive surgery, retinal detachment, corneal transplant; * glaucoma; * pregnancy; * currently participating in another investigational drug or device study; * exclusion criteria during surgery; * other protocol-defined exclusion criteria may apply.

Keywords: cataracts intraocular lens multifocal presbyopia
pain relief during iud insertion in women delivered only by elective cesarean section

Conditions: IUD Insertion Complication

Summary: the aim of the work is to assess the effect of combined misoprostol 200 mcg and isosorbide mononitrate 40 mg versus misoprostol 200 mcg and placebo as local vaginal tablet on the successful iud insertion.

fear of pain during insertion of an iud may deter women from choosing the iud as a method of contraception. according to hubacher et al. predictors of increased pain during iud insertion include nulliparity, age greater than 30 years, lengthier time since last pregnancy or last menses, and not currently breastfeeding. allen et al. predicted pain to be greater based on history of no previous vaginal delivery, and difficulty of the procedure. pharmacological interventions for pain control during iud insertion include analgesics, local anesthetics, and the use of prostaglandins to soften the cervix; however, there is wide variation in the use of these methods . misoprostol has also been proposed as an agent to ease iud insertion and decrease procedure-associated pain . nitrous oxide has been used for years for procedural analgesia in outpatient settings and has recently been investigated as an approach to pain management in the context of iud insertion . sewell and vincent have been offering nitrous oxide for reducing the pain of iud insertion and have had a positive response.

Eligibility criteria:
inclusion criteria:we will include * nonpregnant women, * aged 18-45 years, .delivered before only by elective cs and did not receive any analgesics in the 24 h prior to iud insertion. exclusion criteria:we will exclude * women with any uterine abnormalities as congenital anomalies, * women with endometrial lesions, * women with adenomyosis, * women with fibroids, * women with intrauterine adhesions, * women with chronic pelvic pain, * women with spasmodic dysmenorrhea, * women with abnormal uterine bleeding, * women with history of cervical surgery, .women with allergy to misoprostol or isosorbide mononitrate or any medical disease that contraindicates its use and those who refused to participate in the study.
a study to test the safety/ efficacy of brivaracetam (brv) used as adjunctive treatment in subjects >=16 years of age with partial seizures with or without secondary generalization

Conditions: Partial Seizures With or Without Secondary Generalization; Epilepsy

Summary: the purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam (brv) in focal epilepsy subjects with partial seizures and to evaluate the maintenance of efficacy of brv over time.


Eligibility criteria:
inclusion criteria: * male/female study participant from 16 years of age or older. study participant who are not legal adults may only be included where legally permitted and ethically accepted * study participant completed the treatment period and transition period of ep0083 or is ongoing in n01379 sites in japan * female study participants with childbearing potential are eligible if they use a medically accepted contraceptive method * inclusion criteria for directly enrollers only: study participant has 1 to \<8 partial seizures (according to the 1981 international league against epilepsy (ilae) classification) during the 8 weeks prior to brivaracetam (brv) administration exclusion criteria: * study participant has developed hypersensitivity to any components of the investigational medicinal product (imp) or comparative drugs as stated in this protocol during the course of the core study * severe medical, neurological or psychiatric disorders, or laboratory values which may have an impact on the safety of the study participant * poor compliance with the visit schedule or medication intake in the previous brv studies * planned participation in any other clinical study of another investigational drug or device during this study * pregnant or lactating woman * any medical condition which, in the investigator's opinion, warrants exclusion * study participant has a lifetime history of suicide attempt or has suicidal ideation in the past 6 months * study participant has \>2 x upper limit of normal (uln) of any of the following at the entry visit (ev): alanine aminotransferase (alt), aspartate aminotransferase (ast), alkaline phosphatase (alp), or \>uln total bilirubin (≥1.5x uln total bilirubin if known gilbert's syndrome)

Keywords: brivaracetam epilepsy partial seizures with or without secondary generalization briviact
micro-technique sampling

Conditions: Dermatitis

Summary: this is a single-center, exploratory comparative pilot study to identify the most appropriate method for microbial consortia sampling from the skin. ten subjects are expected to complete the study at one investigative site in the united states. the study will consist of 2 visits, visit 1 (screening), visit 2 (sampling). at visit 1, subjects will be consented and have their eligibility reviewed. visit 1 and visit 2 may be combined into one visit. visit 1 will involve the informed consent process, screening, and enrollment. visit 2 will involve sampling of eight (8) test sites on the back with three (3) different sampling methods: swabbing (2 sites/method), cup scrub (2 sites/method), and tape stripping (4 sites/method). all samples will be returned to kimberly clark then sent to a laboratory for analysis.


Eligibility criteria:
inclusion criteria: * fluent in english, willing and able to read, understand, and sign the informed consent form (icf); * ability to complete the course of the study and comply with instructions; * females aged 18 to 40 years, in good general health as deemed by the investigator (no physical required); * individuals free of any systemic or dermatological disorder, tatoos in the testing area or recent tanning bed exposure * anticipated ability to complete the course of the study and to comply with instructions; * females practicing an acceptable method of birth control * caucasian individuals with fitzpatrick skin type i, ii, or iii
a study of monthly subcutaneous (sc) mircera for maintenance treatment of participants with chronic kidney disease on peritoneal dialysis

Conditions: Anemia

Summary: this single-arm study will assess the efficacy and safety of monthly administration of sc mircera for the maintenance of hemoglobin levels in participants with chronic kidney disease on peritoneal dialysis. participants currently receiving maintenance treatment with sc erythropoietin stimulating agents (esas) will receive monthly sc injections of mircera, with the starting dose derived from the last weekly esa they had been receiving.


Eligibility criteria:
inclusion criteria: * adults greater than or equal to (≥) 18 years of age * chronic kidney disease-related anemia on peritoneal dialysis for ≥3 months * continuous sc maintenance stable esa therapy for 4 weeks prior to study start exclusion criteria: * transfusion of red blood cells during previous 8 weeks * poorly controlled hypertension requiring interruption of esa treatment in previous 6 months * significant acute or chronic bleeding during previous 8 weeks
accuracy assessment of an automatic blood pressure measurement device in adult volunteers

Conditions: Pre Eclampsia

Summary: the research team has developed an automatic blood pressure monitor (sphygmo) to be used for the monitoring and diagnosis of pre-eclampsia in pregnant women, particularly in low-resource settings where current monitoring is limited. 90 adult volunteers will be enrolled by researchers at rice university. the participant will be seated in a comfortable chair with arm at heart level. arm circumference will be measured and a blood pressure cuff will be placed on the arm. the cuff will be inflated and blood pressure measurements will be taken by a commercially available device and by the sphygmo device. blood pressure measurements from both devices will be recorded. the participant's blood pressure will be measured up to 9 times with a waiting period of 45-60 seconds between each measurement. the results of this study will be used to optimize the blood pressure detection algorithm and thus further develop the device.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * willing and able to provide informed consent exclusion criteria: * unable to provide informed consent
a study of mirikizumab (ly3074828) in pediatric participants with crohn's disease

Conditions: Crohn's Disease

Summary: study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. the purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with crohn's disease. study periods for the intervention-specific appendix (isa) will be as follows: * a 12-week induction period * a maintenance period from week 12 to week 52, and * a safety follow-up period up to 16 weeks. the study will last about 74 weeks and may include up to 19 visits.

participants screened in the macaroni-23 platform study could be randomized to mirikizumab to participate in this intervention specific arm of the study.

Eligibility criteria:
inclusion criteria: * participants must have a diagnosis of cd or fistulizing cd, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria. * participants have moderately to severely active cd (as defined by a baseline pcdai score ≥30). * participants must have endoscopy with evidence of active cd defined as ses-cd score ≥6 (or ≥4 for participants with isolated ileal disease) within 1 month of receiving study intervention at week 0. * participants must have a documented history of inadequate response, loss of response or intolerance to at least one medication used to treat cd, which may include immunomodulators, oral or iv corticosteroids, a biologic therapy or a jak inhibitor. exclusion criteria: * participants must not have complications of cd such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestations that might be anticipated to require surgery. * participants must not have an abscess. * participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline.

Keywords: inflammatory bowel disease
clinical indicators and brain image data: a study based on kailuan cohort

Conditions: Brain Diseases; Hypertension

Summary: the investigators will analyze the relationship between the medical history, physiological indicators and the cerebral small vessel disease as well as the structural and functional changes of the brain/head and neck organs in a large sample size of subjects (participants), to identify the influencing factors of the occurrence and development of cerebral small vessel disease as well as the structural and functional changes of the brain/head and neck organs, so as to provide objective clues for early intervention of the disease and improve clinical outcomes.


Eligibility criteria:
inclusion criteria: 1. age from 18 to 90 years old; 2. comes from the kailuan cohort, completed ≥1 visits which the medical history, physiological indicators were measured; 3. without contraindications of ct and mr scan; 4. can cooperate with the measurement of the medical history, physiological indicators and brain imaging. exclusion criteria: 1. known clinical history with congenital or acquired organic diseases (such as aortic stenosis); 2. known history of drug abuse; 3. pregnant and lactating women; 4. with clinical history of psychiatric diseases (such as schizophrenia).
learned resourcefulness intervention

Conditions: Self-Control; Caregiver Burden; Quality of Life

Summary: this study aimed to test the effects of a learned resourcefulness interveniton program on the learned resourcefulness, caregiver burden, quality of life for older family caregivers.

a quasi-experimental trail will be used to test the effects of a learned resourcefulness intervention program on the learned resourcefulness, caregiver burden, quality of life for older family caregivers. through the use of convenience sampling strategy, one teaching medical hospital with approximately 104 older family caregivers in southern taiwan will be recruited and simple randomly assigned based on teaching medical hospital to a learned resourcefulness intervention program experimental group or a wait-list control group. participants in the experimental group will receive the learned resourcefulness intervention program led by researcher, one time per week, 50 minutes for one week, 10 minutes for these weeks; participants in the wait-list control group will continue to receive their home care service. one pre-test and two post-tests, all participants will assessed for learned resourcefulness, caregiver burden, quality of life at baseline, and at 5 and 9 weeks of the study.

Eligibility criteria:
inclusion criteria: * aged 60 and above * family caregivers of disabled adults who received home care service * cognitively intact as assessed by spmsq score of 8 and above * disabled adults will assessed by barthel index score of 60 and bellow * able to answer questions exclusion criteria: * participants with severe mental disabilities
natural dendritic cell vaccines in metastatic melanoma patients

Conditions: Melanoma

Summary: dendritic cells (dcs) are the professional antigen-presenting cells of the immune system. as such they are currently used in clinical vaccination protocols in cancer patients, and both immunological and clinical responses have been observed. several subsets of dendritic cells have been characterized in the peripheral blood. one such subset is referred to as plasmacytoid dendritic cells (pdc), another as myeloid dendritic cells (mydc). to date pdc and mydc have not been evaluated for their capability to induce anti-tumor immune responses in patients. for this reason the investigators will perform a safety and efficacy study with pdc and mydc in stage iv melanoma patients.


Eligibility criteria:
inclusion criteria: * stage iv melanoma according to the 2001 ajcc criteria. limited tumor burden; ldh \< 2x upper limit of normal * histological proof of cutaneous melanoma * melanoma expressing tyrosinase and/or gp100 (approximately 20% of cells or more determined by immunohistochemistry staining) * hla type a2 * wbc \> 3.0 \* 10e9/l, lymphocytes \> 0.8 \* 10e9/l, platelets \> 100 \* 10e9/l, serum creatinine \< 150 umol/l, serum bilirubin \< 25 umol/l, normal liver function * expected adequacy of follow up * written informed consent exclusion criteria: * autoimmune disorders, concomitant use of immunosuppressive drugs * serious concomitant disease, serious active infections, other malignancy in the past 5 years with the exception of curatively treated carcinoma in-situ of the cervix/squamous cell carcinoma of the skin * known allergy to shell fish (vaccine contains klh) * pregnancy or lactation * clinical signs of cns metastases, in patients with a clinical suspicion of cns metastases, a ct scan of the brain should be performed to exclude this * prior chemotherapy, immunotherapy, or radiotherapy within three months before planned vaccination is allowed

Keywords: dendritic cells